Late on a Friday in November 2013, Anne Wojcicki was at a strategy offsite when her executive assistant texted that a package had arrived by courier from the U.S. Food and Drug Administration. Wojcicki had spent years in a grinding back-and-forth with the agency over how 23andMe — her direct-to-consumer genetic testing company, then seven years old — should be regulated, and the courier's arrival carried the specific dread of officialdom rendered physical. She texted back: "Don't sign for it!" Her assistant replied: "It's too late, I already did."
The package contained a warning letter that ordered 23andMe to stop marketing its health-related genetic tests immediately. The FDA's position was blunt: the company was performing what the agency regarded as a medical test without approval and without the oversight of any doctor. Overnight, the most ambitious consumer genetics company in the world was reduced to little more than an ancestry service — a genealogy toy stripped of its reason for being. The company that had been named by Fast Company as the work of "The Most Daring CEO in America," whose $99 saliva test had been Time magazine's Invention of the Year in 2008, was now legally prohibited from telling customers what their DNA meant for their health.
What happened next — the two-year regulatory exile, the internal reinvention, the painstaking FDA submissions, the eventual first-ever direct-to-consumer genetic health test approval — would become the defining chapter of Wojcicki's career. But the courier package also inaugurated a longer, stranger arc: a trajectory that would take 23andMe from startup darling to public company valued at $6 billion, then plunge it into a 98% stock collapse, a catastrophic data breach, the mass resignation of its entire board, a bankruptcy filing, and finally — improbably — a $305 million bid by Wojcicki herself to buy back the company she built, this time through a nonprofit.
This is not a tidy founder story. It is the story of a woman who believed, with a conviction bordering on religious certainty, that giving people access to the code written inside their own cells would transform medicine — and who spent nearly two decades learning that the distance between a beautiful idea and a functioning business can be measured in regulatory letters, board revolts, and billions of dollars of evaporated value.
Part IIThe Playbook
What follows is a distillation of the strategic principles, operational instincts, and leadership patterns that defined Anne Wojcicki's two-decade journey with 23andMe — principles drawn from both her triumphs and her failures, often from the same decision.
Table of Contents
1.Build outside the system you want to change.
2.Make the price the product.
3.Treat controversy as a feature, not a bug.
4.Turn regulatory defeat into a competitive moat.
5.Your database is your business — everything else is distribution.
6.Use personal conviction to survive institutional rejection.
7.Beware the adjacency trap.
8.The one-time purchase problem has no elegant solution.
We were raised to not shy away from conflict. That quality has helped me focus on what I believe is the right thing to do and manage the conflict and criticism that has come our way.
I want the world's data accessible.
I think being on a constraint with money makes you much more creative.
One of the things that got me interested in genetics was the relationship between genes and environment. We are all dealt a certain deck of cards, but our environment can influence the outcomes.
Making personalized medicine a reality will require a strong partnership between 23andMe and the physician and medical communities.
I have always been interested in health care and doing something that is dramatic.
Our approach to medicine is very 19th-century. We are still in the dark ages. We really need to get to the molecular level so that we are no longer groping about in the dark.
If I am fortunate enough to secure the company's assets through the restructuring process, I remain committed to our long-term vision of being a global leader in genetics and establishing genetics as a fundamental part of healthcare ecosystems worldwide.
There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering.
The reality is that the only way change comes is when you lead by example.
There's a beauty in being unrealistic.
By the Numbers
23andMe at a Glance
15M+Customers genotyped worldwide
$6BPeak market capitalization (2021)
~$150MMarket value at bankruptcy filing (2025)
$99Price point that unlocked mass adoption
$305MWojcicki's nonprofit bid to reacquire 23andMe (2025)
80%Customers who consented to research participation
55+Health reports meeting FDA requirements
The Physics Professor's Daughter
The Wojcicki family is the closest thing Silicon Valley has to a royal house, which is to say it is simultaneously extraordinary and slightly absurd. Three sisters — Susan, Janet, and Anne — grew up on the campus of Stanford University, where their father, Stanley Wojcicki, a Polish-born émigré, chaired the physics department, and their mother, Esther, taught journalism at Palo Alto High School and would later be dubbed "the Godmother of Silicon Valley." Mattel would honor the sisters with a line of Barbie dolls in 2023, designed to inspire girls in STEM. The honor is both fitting and surreal: Susan became CEO of YouTube, Janet a professor of pediatrics and epidemiology at UCSF, and Anne the cofounder of one of the most consequential — and controversial — consumer health companies of the twenty-first century.
The household operated on a parenting philosophy Esther later codified in her 2019 book, How to Raise Successful People, organized around the mnemonic TRICK: Trust, Respect, Independence, Collaboration, Kindness. "My parents really looked at us always like mini adults," Anne has said. "They gave us a taste of freedom. And they encouraged it." Stanley brought the rigor of particle physics to dinner-table conversation; Esther brought the journalist's instinct to challenge authority. "I remember them telling me, 'Don't be afraid if someone disagrees with you,'" Anne recalled. It was less a piece of advice than a prophecy.
Anne was the youngest, born July 28, 1973, in San Mateo County. She was scrappy, athletic, contrarian. When her parents suggested she pursue tennis instead of ice skating and refused to pay for her skates, she won competitions to buy them herself and bartered babysitting for lessons. At Gunn High School, teachers recognized a talent for writing and made her editor of The Oracle, the school magazine. She wrote about sports. She played hockey. She was competitive about everything.
She crossed the country to attend Yale, where she earned a B.S. in biology in 1996 while playing on the women's varsity ice hockey team and competing in figure skating. The genetics fascination had been there since childhood — since kindergarten, in fact, when her older sister mentioned genes. "I kept staring at her," Wojcicki later recalled. "I was like, 'But you have shorts on.' It was because they were talking about DNA. And that was the first time I ever heard about DNA and I was fascinated."
The Education of a Disillusioned Analyst
After Yale, Wojcicki did not become a bench scientist. She took a job as a healthcare investment analyst, almost by accident. "My mom was like, 'Just interview for a bunch of stuff and see,'" she has said. "And I very randomly got this job offer for the Wallenberg family in Sweden as an analyst. I had no idea what it was." She paused. "And I kind of took the job mostly because I wanted to wear Ann Taylor clothing, like I thought it would be fun to dress up."
The joke conceals something real. What followed was nearly a decade on Wall Street — at the Wallenberg family's Investor AB, then at Passport Capital — focused primarily on biotechnology companies, a period Wojcicki has described as the equivalent of "getting a Ph.D. and then a postdoc." She studied every major healthcare company. She spoke with CEOs and Nobel Prize winners. She learned the science behind drug development, reimbursement structures, insurance incentive models. And she became, by her own account, disgusted.
"I found that few aspects of healthcare actually were in my best interest," she said at Stanford Biodesign. "I would like to just stay healthy and to never use healthcare, but I found that almost no aspects of what I was investing in were focused on 'How do I stay out of the system?'" She recalled a "panic-attack moment" at an event where insurers and accountants discussed how to "maximize the billing opportunity" when patients sought care. The system, she concluded, was built to monetize illness, not incentivize prevention. Healthcare professionals "don't make money by preaching prevention."
The disillusionment was structural, not personal. She saw how financial incentives encouraged the healthcare system "to not really care for the patients that needed their help the most." The $4 trillion American healthcare apparatus was spectacularly fragmented, riddled with inefficiencies, and — this was the crucial insight — incapable of reforming itself from within. "The healthcare system can't change from within," she later told HBR. "I believe that pretty strongly, even today."
She quit around 2000. Briefly considered taking the MCAT. Didn't. Instead, she began researching what it would take to build something entirely outside the system — something that put the consumer, not the physician, not the insurer, at the center of healthcare.
The ACT-UP Epiphany and the Founding of 23andMe
The intellectual catalyst was unexpected: not a scientific paper or a business plan, but a political movement. Wojcicki was inspired by ACT-UP, the AIDS Coalition to Unleash Power, the activist organization that in the 1980s and 1990s demanded that patients play a greater role in directing research and making their own medical decisions. ACT-UP had forced the FDA to accelerate drug approvals, had rewritten the relationship between patients and the medical establishment. "I started to realize that if you really wanted to understand the human genome and to have a different type of healthcare system, you had to have it driven by the people and for the people," Wojcicki said. The language is deliberate — Lincolnian, even populist.
By 2006, the human genome had been sequenced for three years, and the technology to genotype individuals was becoming dramatically cheaper. Wojcicki saw the convergence: consumer empowerment, falling costs, and the rise of platforms like Facebook and YouTube that were giving ordinary people a voice. If celebrities at West Coast "spit parties" found genetic testing fascinating, she reasoned, middle-class Americans would too. Genealogy was the world's second-most popular hobby after gardening. The market was there.
She cofounded 23andMe — named after the 23 pairs of chromosomes in a normal human cell — with Linda Avey, a genetics expert who had first conceived of the idea, and Paul Cusenza, an engineer and executive. The founding premise was twofold: give individuals direct access to their own genetic information, enabling more personalized medical decisions, and build a massive anonymized database of genetic data for commercial and academic research. "23andMe came out of this idea that we're going to empower people by giving them access to their genetic information and we're going to crowdsource research," Wojcicki said.
Linda Avey was a different kind of cofounder — older, steeped in the genetics establishment, motivated by a deep personal interest in Alzheimer's disease research. She had worked at Affymetrix, a leader in DNA microarray technology, and brought scientific credibility that the Yale biology graduate and Wall Street analyst could not. Cusenza, the technical cofounder, would leave in 2008. Avey's departure, in 2009, was less voluntary. According to a Wall Street Journal story published years later, Wojcicki — then 35 — approached the board with a proposal: fire Avey and let Wojcicki run the company alone. The board complied. "It was not something that I chose," Avey later said. "It came as a total surprise to me and just the whole way it was handled was unfortunate."
The episode revealed something essential about Wojcicki: a conviction that the mission required singular control, a willingness to act on that conviction with speed and finality, and a blind spot about how such actions landed on the people around her. These qualities would define the next fifteen years.
Spit Parties and the Invention of the Year
Wojcicki had no marketing plan. No sales strategy. No comparable models to study. What she had was instinct, connections, and what one observer called "relentless optimism and charisma."
In 2008, she orchestrated a series of celebrity-studded "spit parties" during New York Fashion Week, where Rupert Murdoch and Diane von Furstenberg mingled while dutifully filling 23andMe's test tubes with their saliva. The New York Times covered the events. Wendi Murdoch and Harvey Weinstein provided backing. The entire affair was engineered to make genetic testing feel glamorous, accessible, fun — the opposite of the clinical, paternalistic experience of American medicine.
That same year, Time magazine named the 23andMe retail saliva genetic test its Invention of the Year. The test, initially priced at $999, provided customers with information about their genetic traits, estimates of predisposition toward various health conditions, and ancestry composition. Customers could access results online — a radical departure from the physician-mediated model that governed virtually all medical testing in America.
Google invested $3.9 million in 2007. The timing was not coincidental: Wojcicki had married Google cofounder Sergey Brin in May 2007. The entanglement of personal and professional — of Google money, Google computing power, and a Google cofounder's wife running a company that aspired to become the Google of DNA — would become a recurring source of fascination, suspicion, and, eventually, dismissal.
I remember in the early days of Google, Larry would say, 'I just want the world's data on my laptop.' I feel the same way about health care. I want the world's data accessible.
— Anne Wojcicki, New York Magazine, 2014
The comparison to Google was not accidental. Wojcicki wanted to do with DNA what her then-husband's company had done with information: organize it, make it searchable, and make it universally accessible. The difference was that Google organized the world's data for free, monetized through advertising. 23andMe was asking people to pay $99 for the privilege of handing over their most intimate biological information. The transaction was, from the beginning, more complex than it appeared.
The Parkinson's Connection
The personal stakes were never abstract. Sergey Brin's mother, Eugenia, had been diagnosed with Parkinson's disease in 1998, at roughly the same age her beloved aunt Serafima had developed the condition in Moscow decades earlier. Parkinson's is inherited in only about 10 percent of cases, but the Brin family pattern was troubling. When 23andMe genotyped Brin, the results confirmed he carried a LRRK2 mutation associated with elevated Parkinson's risk. Wojcicki herself was found to be a carrier for Bloom's syndrome.
The couple had two children. Wojcicki tested her son's DNA at birth. She tested her daughter's amniotic fluid in utero. "If you are going to have children I think you have a responsibility to know if you are carrying anything," she told The Guardian in 2016. "I personally would rather go into the decision of having a child knowing this information because then I feel like I could be a better informed potential parent."
The Brin Wojcicki Foundation, co-directed by the couple, donated to the Michael J. Fox Foundation for Parkinson's research, to the Electronic Frontier Foundation, and $500,000 to the Wikimedia Foundation in 2011. Their collective wealth — estimated at more than $30 billion, much of it in special B-class Google stock — placed them ninth among U.S. families in charitable giving. They were, for a time, discussed as Generation X's answer to Bill and Melinda Gates.
But Wojcicki knew something about being appended to someone else's story. She remembers googling her own name before the marriage was announced. "It came up with a blank result," she said. "I took screenshots because I thought to myself, 'this is fundamentally who I am.'" At the World Economic Forum in Davos, where color-coded name tags created a notorious caste system, she wore the badge of a "partner" — a spouse. "I remember specifically how people would just look at your badge and be like, 'Oh, you're a partner,'" she said. "And then they ignore you."
The Square Peg in the Round Hole
The FDA problem was structural, not adversarial — at least not initially. The agency's approval system was designed to evaluate individual medical tests, one by one. 23andMe tested roughly a million components of a person's DNA simultaneously. Filing for a million individual approvals was, as Wojcicki put it, impossible. "The service the company provides is so novel that it does not fit into the F.D.A.'s framework," she said at a Fortune Most Powerful Women dinner in December 2013, weeks after the warning letter arrived. "Like a square peg in a round hole."
But Wojcicki also admitted culpability. In May 2013, the FDA had asked 23andMe for additional information. The company did not respond quickly enough. "We completely recognize we're behind schedule; we failed to communicate proactively," she said. "They're a very important partner, and everyone is focused on resolving it."
Her sister Susan, seated beside her at the Fortune dinner — the two most prominent women in Silicon Valley, raised in the same house, navigating adjacent regulatory minefields — offered the Google perspective. "In some ways, we're in similar spaces, which is companies doing things that have never been done before," Susan said. "So there are questions: 'What are the implications of this?' Lots of times these become more accepted as the technology gets used."
From 2013 to 2015, 23andMe entered a regulatory purgatory. Customers could access only ancestry-related test results. Health information was locked away. The company hemorrhaged relevance. But Wojcicki did something counterintuitive: rather than fighting the FDA or attempting an end-run, she chose full compliance. She overhauled internal processes. She hired regulatory experts. She submitted painstaking documentation proving the accuracy and reliability of each individual test.
In 2015, the FDA approved 23andMe to sell a genetic test capable of detecting more than 30 autosomal recessive disorders — conditions like cystic fibrosis, sickle cell anemia, and Tay-Sachs disease that manifest when two copies of a disease-causing gene are present. It was the first direct-to-consumer genetic test ever approved for marketing by the FDA. The square peg had, through years of patient grinding, reshaped the hole.
I am never as brash and confident as I was five years ago about anything that has to do with regulation. It was a bump in the road but our intentions were always in the right spot.
— Anne Wojcicki, The Guardian, 2016
The Divorce, the Affair, and the Badge
In 2013, while 23andMe was reeling from the FDA crackdown, Wojcicki's marriage to Brin was collapsing. Brin had begun a relationship with Amanda Rosenberg, a Google Glass marketing manager in her mid-20s, who had herself left her boyfriend — a valued executive in Google's Android division — for the company's cofounder. The separation was covered by Vanity Fair in lurid detail. Los Altos, the suburb where Brin and Wojcicki had invested in children's science centers and farm-to-fork restaurants, was revealed as the stage set for a drama that Silicon Valley's data-driven optimists preferred to believe happened only to other people.
The divorce was finalized in 2015. The terms of the settlement were never disclosed, but the couple shared a family office until late 2017. Wojcicki's position became, in the peculiar calculus of tech-world status, both more precarious and more clarified. She was no longer the wife of a Google cofounder. She was the CEO of a company that had survived the FDA, emerged with the only approved direct-to-consumer health test on the market, and now needed to prove it could build a real business.
"There are people who wouldn't talk to me for years and years," Wojcicki said in 2021, reflecting on the long stretch when her identity was subsumed into Brin's. "I remember those days really well." The Davos badge story — "Oh, you're a partner" — was not just an anecdote. It was a thesis. About how power is perceived, how women are categorized, and how the only reliable escape from someone else's shadow is building something that cannot be ignored.
The Billion-Dollar Database and the Drug Discovery Bet
By 2016, 23andMe had genotyped more than one million people worldwide. The database — vast, growing, uniquely consented — was the company's true asset, more valuable than the test kits themselves. Eighty percent of customers agreed to allow their anonymized data to be used for research. Wojcicki had built, in effect, the world's largest crowdsourced genetic research platform.
The scale enabled discoveries that traditional academic research could not match. 23andMe researchers could recruit participants for multiple studies simultaneously, correlating genetic variants with self-reported health conditions across populations of millions. Pharmaceutical companies took notice. Partnerships formed. The data became the foundation for a bet that would define 23andMe's ambitions — and, eventually, hasten its collapse.
Wojcicki launched a therapeutics division, building a drug discovery operation from scratch within a consumer genetics company. The logic was seductive: leverage the database to identify drug targets, then develop treatments for serious unmet medical needs. It was a move from consumer tech into Big Pharma territory, from $99 spit kits to billion-dollar clinical trials.
In 2021, 23andMe went public through a SPAC merger with VG Acquisition Corp., created by Richard Branson's Virgin Group. The deal valued the company at $3.5 billion. On the first day of trading, Wojcicki's approximately 99 million shares were worth $13.32 each — putting her personal stake above $1.3 billion. She was, finally and unambiguously, a self-made billionaire. She was no longer appended to anyone's story.
"I feel super, super lucky. I have money — and I absolutely try to use my money to drive change," she said. According to a Crunchbase analysis, Wojcicki had invested in 14 startups with at least one female founder out of 29 overall investments — by far the most gender-diverse track record among all founders whose companies went public that year in deals valued at $1 billion or more.
The peak, however, was brief. The market capitalization touched $6 billion. Then it began to fall.
The Unraveling
The collapse of 23andMe is not a single event but an accumulation of compounding failures, each feeding the next. Consumer demand for DNA testing kits plateaued — a structural problem no amount of marketing could solve. People only need their DNA tested once. There is no natural subscription cadence, no recurring revenue engine, no reason to spit into a second tube. The company attempted to build subscription products offering ongoing genetic insights, but the model never generated the customer engagement Wojcicki expected.
Then came the data breach. In 2023, hackers accessed the genetic information of 6.9 million 23andMe customers over a five-month period. The breach was catastrophic not merely in scale but in kind: genetic data is immutable. You cannot change your DNA the way you change a password. A subsequent lawsuit alleged that 23andMe had failed to notify Chinese and Ashkenazi Jewish customers that their data had been specifically targeted. The breach confirmed every fear that privacy advocates had voiced since the company's founding.
Meanwhile, the therapeutics division — the grand bet on drug discovery — was consuming resources without producing revenue. The company was still years away from any commercial drug, competing against pharmaceutical giants with decades of infrastructure. In November 2024, 23andMe shut down its drug discovery business entirely and announced a restructuring to "streamline operations, reduce costs and position company for the future."
The share price, which had peaked above $13 at the SPAC debut, fell below $1. Then below 50 cents. Then to 34 cents, giving the company a market value of roughly $173 million — a decline of more than 98% from its peak.
Inside the company, former executives describe a pattern. Wojcicki, they say, had a tendency to put herself at the center of all decisions, slowing the organizational machine as market forces accelerated. She crowdsourced solutions through her vast network of Silicon Valley luminaries rather than empowering her own leadership team. The North Star at 23andMe, said one former senior leader, was: "Is Anne happy?"
Wojcicki pushed back against these characterizations. "I have always made decisions based on conditions in a given moment," she said. She pointed to the biotech market collapse, the pandemic, and rising competition. "It'd be wrong to conflate those issues with leadership style."
The Board That Left
In September 2024, all seven independent board members of 23andMe resigned simultaneously, issuing a public letter that rebuked Wojcicki's strategic direction. The board — which included Roelof Botha, managing partner of Sequoia Capital, and Neal Mohan, CEO of YouTube, who had known Wojcicki for years and worked closely with her late sister Susan — wrote that while they "wholeheartedly" believed in the company's mission, they could not support Wojcicki's plan.
The plan in question was a take-private bid. As 23andMe's valuation cratered, Wojcicki proposed buying the company herself, initially at 40 cents per share — a price that offered shareholders no premium over the already-devastated stock. The board formed a special committee to evaluate the proposal and protect shareholders' interests. They rejected the initial offer and pressed for a detailed, fully financed plan. It never materialized.
Wojcicki, who controlled 49.75% of the company's voting rights, told the board she would not accept third-party bids. The asymmetry was stark: she had enough control to block any alternative deal, but not enough to unilaterally force her own. Locked in a standoff, the directors chose the nuclear option. Mass board resignations are almost unheard of in the startup world. This was a blue-chip board walking away in unison.
"I'd love to know more about that," a reporter told Wojcicki. "Me too, frankly," she quipped, before repeating her only public comment: the board's actions surprised her.
She was now the sole remaining board member, simultaneously CEO and chair of a company with no independent governance, a collapsing stock price, and 15 million customers' genetic data in the balance.
Bankruptcy, Regeneron, and the Nonprofit
In March 2025, 23andMe filed for Chapter 11 bankruptcy. Shares plunged 50% to 88 cents. Anne Wojcicki resigned as CEO. California's attorney general urged customers to consider deleting their data. The prospect of the company's genetic database — the biological information of 15 million human beings — being auctioned to the highest bidder triggered an outcry.
Regeneron Pharmaceuticals, a New York-based biotech giant, won the initial court-supervised auction with a bid of $256 million. Despite pledges to honor existing privacy policies, more than two dozen state attorneys general sued to halt the deal, arguing that genetic information constituted a fundamentally different kind of property than real estate or office furniture. The legal battle centered on an unanswerable question: what happens to immutable biological data when the company entrusted with it ceases to exist?
The bidding was reopened. And then Wojcicki made her move.
In May 2025, she established the TTAM Research Institute — the acronym a nod to "twenty-three and me" — a nonprofit public benefit corporation designed to acquire 23andMe's assets and use the genetic data for medical research. On June 5, 2025, TTAM submitted a winning bid of $305 million. On June 30, 2025, a bankruptcy judge in St. Louis approved the sale, writing that the transaction "involves a sale of customer data only in a technical sense." The nonprofit pledged to improve privacy policies and continue allowing customers to delete their data at will.
Five states — California, Kentucky, Tennessee, Texas, and Utah — remained actively opposed. The story is not over.
Late on a Friday in November 2013 I was at a strategy offsite when my executive assistant texted that we had received a package by courier from the U.S. Food and Drug Administration. Hoping to gain as much time as possible, I texted back, 'Don't sign for it!'
— Anne Wojcicki, HBR, 2020
The Code Inside You
There is a particular kind of founder who cannot let go — who identifies so completely with the company they built that the boundary between self and institution dissolves. Wojcicki is this kind of founder. She tested her son's DNA at birth. She tested her daughter in utero. She wore Lululemon shorts to work and biked to the office and kept a pet dog policy and organic lunches and an open-access desk in a glass cube. She lived inside 23andMe the way she believed people should live inside their own genomes: with radical transparency, total access, and the conviction that knowledge — any knowledge, however uncomfortable — is always better than ignorance.
"I loved genetics and the idea that you have a code inside of you that interacts in your environment and determines how your body works," she told Stanford Biodesign. "It's absolutely captivating."
The captivation never wavered. Not through the FDA shutdown, not through the divorce, not through the stock collapse, not through the board revolt. In 2023, she wrote a Fortune essay arguing that the promise of the Human Genome Project — completed twenty years earlier — remained unfulfilled, not because of insufficient scientific progress but because of "a failure to implement widespread genetic testing and personalized medicine for all who could benefit from it." More than 80% of people with BRCA1/2 variants didn't know they had them. Approximately 10% of African Americans over 60 with congestive heart failure carried a TTR variant they'd never been tested for. Patients could experience 30% fewer serious adverse drug reactions if medications were tailored to their genes.
The data supported her. The business did not.
Susan Wojcicki died on August 9, 2024, at age 56, of non-small-cell lung cancer. She had stepped down from YouTube the previous year to focus on "family, health, and personal projects." The eldest sister — Google's sixteenth employee, the woman who rented her Menlo Park garage to Larry Page and Sergey Brin, who oversaw AdWords and the acquisition of YouTube and became the company's senior vice president — was gone. Anne Wojcicki, who had shared a stage with Susan at the Fortune Most Powerful Women dinner in 2013, who had navigated parallel regulatory minefields, who had raised three daughters of a Silicon Valley royal house, was now running a nonprofit dedicated to preserving the genetic data of 15 million strangers.
On a call with a reporter in late 2024, asked to reflect on her leadership, Wojcicki demurred. "What will be most interesting is writing the story in three or four years," she said. It was both a deflection and a dare.
Somewhere in the TTAM Research Institute's servers — in data stripped of personally identifiable information but dense with the molecular signatures of ancestry, disease risk, and the irreducible particularity of individual human beings — 15 million genomes wait. They contain secrets about Parkinson's and breast cancer and the way warfarin is metabolized and whether you have an aversion to coriander. They are the residue of a bet placed in 2006: that the code inside you belongs to you, and that knowing it will make you free.
The bet is still open. Anne Wojcicki — no longer CEO, no longer married to a billionaire, no longer on anyone's badge as a "partner" — is still placing it.
9.Centralized control scales until it doesn't.
10.Separate your identity from the company's identity — or don't, and pay the price.
11.Privacy is not a feature — it is existential infrastructure.
12.Mission permanence can outlast corporate form.
Principle 1
Build outside the system you want to change
Wojcicki's foundational insight — the one that preceded 23andMe by years — was that the American healthcare system was structurally incapable of reforming itself. The $4 trillion apparatus was too fragmented, too riddled with misaligned incentives, too deeply invested in treating illness rather than preventing it. Her decade as a healthcare investment analyst gave her the analytical vocabulary to diagnose the problem; her inspiration from ACT-UP gave her the political framework for the solution. Change had to come from consumers, not providers.
This is not the standard Silicon Valley "disruption" playbook. Wojcicki was not trying to make healthcare marginally more efficient. She was attempting to route around the entire system — to give consumers direct access to information that the medical establishment had traditionally gatekept, and to use that access as the foundation for a fundamentally different model of research. The decision to sell directly to consumers, without physician intermediation, was not a marketing tactic. It was the philosophical core of the company.
The lesson endures even as the company falters: the deepest innovations often begin not with a technology but with a structural diagnosis. Wojcicki's technology was genetic testing. Her insight was institutional.
Tactic: Before building a product, map the incentive structures of the industry you're entering — and decide whether you're optimizing within those structures or building an alternative to them.
Principle 2
Make the price the product
23andMe initially priced its test at $999. Adoption was modest. In 2012, the company dropped the price to $99 — and demand exploded. "We sold 17-18,000 kits by the end of the day," Wojcicki recalled. "And that was actually frankly all of our inventory." The price cut was not incremental. It was a 90% reduction that revealed massive latent demand invisible at the original price point.
The $99 price also served a strategic function beyond revenue: it lowered the barrier to building the database. Every kit sold added another genome to the research platform. The consumer product was, in effect, a data acquisition mechanism subsidized by the consumer herself. The customer paid to give 23andMe its most valuable asset.
💰
Price as Strategy
How 23andMe's pricing decisions served multiple functions simultaneously
Price Point
Consumer Function
Strategic Function
$999 (2007)
Luxury/novelty item
Slow database growth
$99 (2012)
Mass-market accessibility
Rapid database scaling
Subscription (2022+)
Ongoing engagement
Revenue diversification attempt
Tactic: Test whether your growth ceiling is a demand problem or a pricing problem by experimenting with dramatic (not incremental) price reductions, and measure whether the volume increase generates strategic value beyond direct revenue.
Principle 3
Treat controversy as a feature, not a bug
Wojcicki understood from the beginning that circumventing the medical establishment would generate opposition. She planned for it. "We always knew there would be controversy," she told HBR. "In some ways, that was part of the plan." The controversy around direct-to-consumer genetic testing — questions about genetic privacy, the reliability of health-risk assessments without physician guidance, the implications of learning devastating medical information from a website — generated attention that no marketing budget could buy.
The spit parties were controversy as spectacle. The FDA crackdown was controversy as existential threat. The difference is that Wojcicki expected the former and was blindsided by the latter — not by the fact of regulatory scrutiny, but by its severity and timing. The lesson is that controversy is a useful accelerant only when the founder retains the ability to control the narrative. When the FDA issued its warning letter, the narrative escaped Wojcicki's control entirely.
Tactic: If your product inherently challenges an established order, prepare for controversy with the same rigor you apply to product development — scenario-plan the regulatory, legal, and public relations dimensions before they arrive.
Principle 4
Turn regulatory defeat into a competitive moat
The FDA shutdown of 23andMe's health testing in 2013 was the lowest point in the company's history. Wojcicki's response — full compliance rather than legal confrontation — was both principled and strategic. The two-year process of submitting individual test validations to the FDA was grueling, expensive, and boring. It was also the best possible investment in competitive positioning.
When 23andMe emerged in 2015 with the first-ever FDA-approved direct-to-consumer genetic health test, it had something no competitor could replicate without enduring the same regulatory gauntlet. The approval was not merely permission. It was a moat. The company's willingness to submit to the agency's demands — to be, as Wojcicki put it, "not as brash and confident as I was five years ago" — transformed a devastating setback into a durable advantage.
Tactic: When a regulator blocks your path, evaluate whether full compliance — however painful — will create a barrier to entry that protects you from future competitors more effectively than any product feature.
Principle 5
Your database is your business — everything else is distribution
The $99 kit was a consumer product. The database it generated was a platform. Wojcicki recognized early that the value of 23andMe scaled not with kit sales but with the size and diversity of the genetic database. "We were like 'Let's go for a million,'" she said, "and then at a million, we said, 'Wow we can really do some crazy things at 10 million.'" Every genome added made every other genome more valuable — a classic network effect, applied to biology.
The database enabled pharmaceutical partnerships, academic collaborations, and internal drug discovery. It attracted investment. It was the asset that made the SPAC possible. And it was the asset that made the bankruptcy so contentious — because 15 million genomes in a court-supervised auction is not the same as 15 million email addresses.
Tactic: Identify the asset in your business that appreciates with scale and orient every other function — pricing, marketing, partnerships — around growing that asset, even if short-term revenue suffers.
Principle 6
Use personal conviction to survive institutional rejection
Wojcicki's belief that individuals are entitled to their own genetic information was not a marketing position. It was a personal creed, forged through her own experience testing her children's DNA, through her ex-husband's Parkinson's risk, through watching the healthcare system fail the people it was supposed to serve. This conviction sustained her through the FDA shutdown, the divorce, and the stock collapse in ways that purely financial motivation could not have.
The danger of mission-driven conviction is that it can calcify into stubbornness, and the line between the two is visible only in retrospect. Wojcicki's refusal to accept third-party bids for 23andMe — her insistence that she alone should control the company's future — was experienced by her board as obstruction, not vision.
Tactic: Cultivate a conviction deep enough to sustain you through existential crises, but build mechanisms — trusted advisors, independent governance, structured dissent — that can distinguish conviction from rigidity in real time.
Principle 7
Beware the adjacency trap
The move from consumer genetic testing into pharmaceutical drug discovery was intellectually coherent and strategically catastrophic. Wojcicki saw the database as a launchpad into therapeutics — a market with vastly higher margins and transformative potential. The logic was sound. The execution underestimated everything: the capital requirements, the timelines, the organizational complexity, and the competitive landscape of an industry dominated by companies with decades of infrastructure.
⚠️
The Adjacency Trap
When core-asset leverage leads into markets with fundamentally different economics
Consumer Genetics
Drug Discovery
Low marginal cost per customer
Billions per drug candidate
Months to market
10-15 year development cycles
Consumer brand loyalty
Regulatory and clinical expertise
Revenue from day one
Revenue only upon FDA approval
The therapeutics division drained resources that the consumer business desperately needed and was shut down in 2024 without producing a commercial drug. The adjacency looked like a natural extension of 23andMe's strengths. It was, in practice, a bet that required an entirely different company.
Tactic: Before leveraging a core asset into an adjacent market, stress-test whether the new market's economics, timelines, and competitive dynamics are compatible with your existing organizational DNA — not just your data.
Principle 8
The one-time purchase problem has no elegant solution
People need their DNA tested once. This is a feature for the consumer and a catastrophe for the business. 23andMe's entire consumer model rested on an act that, once completed, eliminated the customer's reason to return. Subscription products offering ongoing genetic insights and health reports were an attempt to solve this structural problem, but they never generated meaningful engagement. The company explored telehealth acquisitions, wellness services, and ancestry updates, but none replicated the urgency of the initial purchase.
This is not a failure of execution. It is a failure of category. Some products are inherently one-time transactions, and no amount of product innovation can convert them into recurring revenue streams without fundamentally changing what the product is.
Tactic: If your core product is a one-time purchase, design the business model around the data or platform that the purchase generates — not around converting the consumer into a subscriber.
Principle 9
Centralized control scales until it doesn't
Wojcicki's tendency to put herself at the center of all decisions worked brilliantly in the early stages of 23andMe. A startup navigating unprecedented regulatory terrain, with no comparable business models and an adversarial relationship with the medical establishment, needed a singular decision-maker with deep conviction. The removal of cofounder Linda Avey in 2009, however ruthless, gave Wojcicki the uncontested authority she believed the mission required.
But the habits of a startup founder become liabilities at scale. Former executives describe a pattern of senior leaders unable to run their departments autonomously, of strategic decisions funneled through Wojcicki's personal network rather than the company's management team, of latencies introduced by the CEO's need to be involved in everything. The mass board resignation was the terminal expression of a governance model in which one person held 49.75% of voting rights, all institutional authority, and no institutional accountability.
Tactic: As the company scales, audit which decisions genuinely require founder involvement and delegate everything else with genuine authority — not the appearance of delegation with a hidden veto.
Principle 10
Separate your identity from the company's identity — or don't, and pay the price
Wojcicki tested her children's DNA. She wore spandex bike shorts to investor meetings. She kept an open-access desk. She described 23andMe's mission in language indistinguishable from her personal convictions. The company was not a vehicle for her vision — it was her vision, embodied in corporate form. This fusion of self and institution generated extraordinary energy in the early years and extraordinary dysfunction in the later ones.
When the company's valuation collapsed, Wojcicki experienced it as a personal affront. When the board resigned, she experienced it as betrayal. When Regeneron bid to acquire the company's assets, she experienced it as an existential threat to something inseparable from her own identity. The $305 million nonprofit bid to reacquire 23andMe was not a financial transaction. It was a rescue mission for a part of herself.
Tactic: Recognize that the fusion of founder identity and company identity is a source of power and a source of blindness — and build structures that can absorb the shock when the two are forcibly separated.
Principle 11
Privacy is not a feature — it is existential infrastructure
The 2023 data breach — 6.9 million customer accounts compromised over five months — destroyed trust in a way that no product update could repair. Genetic data is not a credit card number. It cannot be changed. It cannot be revoked. It belongs to the customer's children and their children's children. When 23andMe failed to protect it, the damage was not reputational but ontological: the company's entire value proposition rested on trust, and that trust was shattered.
The breach led to a $30 million lawsuit, state attorney general interventions, and a wave of customers deleting their data. It also transformed the bankruptcy proceedings from a routine corporate restructuring into a constitutional question about the nature of biological information as property.
Tactic: If your business stores data that is immutable and deeply personal, invest in security and privacy infrastructure as though the company's survival depends on it — because it does.
Principle 12
Mission permanence can outlast corporate form
The most remarkable thing about the 23andMe story is not the rise or the fall but the persistence of the mission through radical changes in corporate form. Wojcicki's conviction that people should have access to their own genetic information and that crowdsourced genomic data can transform medicine survived a startup, a SPAC, a public company, a bankruptcy, and a nonprofit acquisition. The legal entity changed. The leadership structure changed. The stock price went to zero. The mission didn't move.
The creation of TTAM Research Institute — a nonprofit designed to hold 15 million genomes in perpetuity for medical research — is either the final expression of a founder's unshakeable vision or the final act of a founder who cannot let go. It might be both. The distinction may not matter if the research actually gets done.
Tactic: If your mission is genuinely larger than any single corporate structure, design it to survive the death of the company — through nonprofit conversion, open-source release, or institutional endowment.
Part IIIQuotes / Maxims
In her words
The healthcare system can't change from within. And I believe that pretty strongly, even today, that the $4 trillion that goes into healthcare, the spectacular fragmentation just enables inefficiencies, and that people are not genuinely driven to have change.
— Anne Wojcicki, HBR IdeaCast, 2021
There are people who wouldn't talk to me for years and years. I remember those days really well. I remember specifically how people would just look at your badge and be like, 'Oh, you're a partner.' And then they ignore you.
— Anne Wojcicki, Fortune, 2021
I loved genetics and the idea that you have a code inside of you that interacts in your environment and determines how your body works. It's absolutely captivating.
— Anne Wojcicki, Stanford Biodesign
If you are going to have children I think you have a responsibility to know if you are carrying anything. I personally would rather go into the decision of having a child knowing this information.
— Anne Wojcicki, The Guardian, 2016
What will be most interesting is writing the story in three or four years.
— Anne Wojcicki, Fortune, 2024
Maxims
Your genome belongs to you. The most radical act in modern healthcare is giving people access to information the system was designed to keep from them.
Invest a decade before you build. Wojcicki's ten years as a healthcare analyst were not a detour — they were the education that made 23andMe possible.
Controversy is a resource, not a risk — until it becomes a risk. Planned controversy generates attention; unplanned controversy generates existential threats. Know the difference.
Price is a hypothesis, not a number. A 90% price reduction didn't just increase sales — it revealed a market that didn't exist at the original price.
The database is the business. Consumer products generate revenue; platforms generate compounding value. Build the platform.
Compliance can be a weapon. Full regulatory compliance, endured with patience, creates moats that speed cannot replicate.
One-time products require platform economics. If the customer has no reason to return, the business must extract value from what the customer left behind.
Mission without governance is autocracy. The deepest conviction requires the strongest institutional checks — precisely because conviction blinds.
Identity is not equity. A founder who cannot distinguish herself from the company will experience every corporate setback as a personal wound, and every governance check as an attack.
Data permanence demands trust permanence. If the data you hold cannot be changed, the trust you build cannot be broken — or the consequences are irreversible.
